Editorials

Smoking cessation agents and suicide

BMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b4360 (Published 05 November 2009) Cite this as: BMJ 2009;339:b4360
  1. Jill E Lavigne, associate professor12
  1. 1Wegmans School of Pharmacy, St John Fisher College, Rochester, New York, NY 14618, USA
  2. 2Department of Veterans Affairs, Canandaigua VA Medical Center, Veterans Integrated Service Network 2, Center of Excellence, Canandaigua, New York, USA
  1. jlavigne{at}sjfc.edu

    The risk is uncertain, so patients should make an informed decision

    Success in giving up smoking can be improved through social support, problem solving or skills training, and various drugs. A combination of drugs and other treatments is most effective.1 Drugs include nicotine replacement products, varenicline (Champix), and bupropion (Zyban and generics). Varenicline and bupropion inhibit the craving to smoke through unknown mechanisms. Both drugs influence the dopamine system, which regulates cognition, mood, and behaviour.2 Both varenicline and bupropion have been associated with “changes in behaviour, agitation, depressed mood, suicidal ideation, and attempted and completed suicide” in patients who had no psychiatric history and were not taking psychotropics.3 4 Nicotine replacement products have no such known associations.3 In the linked study (doi:10.1136/bmj.b3805), Gunnell and colleagues report the first retrospective cohort study to examine suicidal thoughts and behaviours after exposure to smoking cessation products.5

    In the United States, changes to labelling of varenicline have been based on biological plausibility and voluntary spontaneous reports, which represent …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe